Compare Crispr Therapeutics AG (CRSP) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Grab Holdings Ltd. — how do they compare? Crispr Therapeutics AG trades at $50.91 (market cap $4.97B), while Grab Holdings Ltd. trades at $3.81 (market cap $15.54B). The key difference: Grab Holdings Ltd. is far larger — about 3.1× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CRSP | GRAB | |
|---|---|---|
Market Cap | $4.97B | $15.54B |
Sector | Health | Technology |
52-Week High | $76.78 | $6.45 |
52-Week Low | $44.34 | $3.27 |
Enterprise Value | $3.32B | $11.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
GRAB trades at $3.94, up 0.25% on the day, with a bullish technical signal and strong analyst support. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing significant improvement from prior losses. Revenue growth continues, reaching $3.37B in 2025. Recent news highlights market outperformance and investor attention, though the stock reacted negatively to Uber CEO's board departure in early July 2026.
Outlook remains positive with 91.67% analyst buy ratings and $5.45 consensus target, implying 38% upside. Key risks include competitive pressures in ride-hailing, execution challenges in expanding financial services, and potential market volatility. Profitability trajectory and cash flow sustainability are critical for maintaining investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
